At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Not Yet Opened 05-09 16:00:00 EDT
5.17
+0.02
+0.39%
盘后5.17
+0.000.00%
19:21 EDT
High5.21Low5.10Vol792.05K
Open5.17D1 Closing5.15Amplitude2.14%
Mkt Cap737.57MTradable Cap671.07MTotal Shares142.66M
T/O4.10MT/O Rate0.61%Tradable Shares129.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Aurinia Highlights LUPKYNIS Success in Lupus Treatment
TIPRANKS  ·  05-09 20:21
Aurinia Highlights LUPKYNIS Success in Lupus Treatment
BRIEF-Aurinia Presents Data Reinforcing Lupkynis® Safety And Efficacy For People With Lupus Nephritis At Congress Of Clinical Rheumatology East 2024
Reuters  ·  05-09 19:45
BRIEF-Aurinia Presents Data Reinforcing Lupkynis® Safety And Efficacy For People With Lupus Nephritis At Congress Of Clinical Rheumatology East 2024
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Business Wire  ·  05-09 18:00
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
Aurinia Pharmaceuticals to Engage at RBC Healthcare Conference
TIPRANKS  ·  05-07 18:37
Aurinia Pharmaceuticals to Engage at RBC Healthcare Conference
BRIEF-Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Reuters  ·  05-07 18:08
BRIEF-Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
Insider Monkey  ·  05-04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
Aurinia Pharmaceuticals’ LUPKYNIS: A Strong Buy on Surging Sales and Positive Market Indicators
TIPRANKS  ·  05-03
Aurinia Pharmaceuticals’ LUPKYNIS: A Strong Buy on Surging Sales and Positive Market Indicators
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
seekingalpha  ·  05-03
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Zacks  ·  05-02
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia Pharma GAAP EPS of -$0.07 beats by $0.07, revenue of $50.3M beats by $3.23M
seekingalpha  ·  05-02
Aurinia Pharma GAAP EPS of -$0.07 beats by $0.07, revenue of $50.3M beats by $3.23M
Aurinia Pharmaceuticals Q1 2024 GAAP EPS $(0.07) Beats $(0.14) Estimate, Sales $50.300M Beat $47.453M Estimate
Benzinga  ·  05-02
Aurinia Pharmaceuticals Q1 2024 GAAP EPS $(0.07) Beats $(0.14) Estimate, Sales $50.300M Beat $47.453M Estimate
Press Release: Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Dow Jones  ·  05-02
Press Release: Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
TIPRANKS  ·  05-02
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  05-02
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
BRIEF-Aurinia Underscores Enduring Commitment To People Living With Lupus Nephritis Through Innovative Advocacy And Education Initiatives
Reuters  ·  05-01
BRIEF-Aurinia Underscores Enduring Commitment To People Living With Lupus Nephritis Through Innovative Advocacy And Education Initiatives
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Business Wire  ·  05-01
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Aurinia gains on Lupkynis label update
seekingalpha  ·  04-30
Aurinia gains on Lupkynis label update
Aurinia’s LUPKYNIS Wins FDA Label Update
TIPRANKS  ·  04-30
Aurinia’s LUPKYNIS Wins FDA Label Update
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Business Wire  ·  04-30
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
seekingalpha  ·  04-18
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--